• 作者：Shenglin Ma ; MD^a ; ^c ; Wenzhe Wang ; PhD^b ; ^c ; Bing Xia ; MD^a ; Shirong Zhang ; MSc^a ; ^c ; Haining Yuan ; MSc^b ; ^c ; Hong Jiang ; MD^a ; Wen Meng ; MD ; MSc^a ; Xiaoliang Zheng ; PhD^b ; ^c ; Xiaoju Wang ; PhD^b ; ^c ; ^{wangxj@zjams.com.cn" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Lung cancer ; Serum biomarkers ; Risk factors ; Early detection ; LDCT
• 刊名：EBioMedicine
• 出版年：2016
• 出版时间：September 2016
• 年：2016
• 卷：11
• 期：Complete
• 页码：210-218
• 全文大小：1078 K

•

A multicentric, case–control study was conducted to identify serum proteins for diagnosing lung cancer.

•

A 4-marker panel improved lung cancer prediction beyond that of known risk factors.

•

The biomarkers can detect lung cancer especially stage I–II from healthy controls or benign nodule patients.

Currently, low dose chest computed tomography (LDCT) leads to a high false-positive result. Here we identified a panel of four serum proteins, which provides the potential for accurate diagnosis of lung cancer in a multicentric study. More importantly, the biomarkers allowed accurate detection of lung cancer cases especially stage I-II cases from normal and benign nodule subjects. These results suggest that the 4-protein panel might be a useful biomarker for diagnosing lung cancer patients and help discriminate early stage patients, which may serve as an adjuvant diagnosis tool for LDCT scanning in the future.